Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 1.06B | 1.08B | 947.85M | 983.11M | 839.99M |
Gross Profit | 314.44M | 311.94M | 260.99M | 261.92M | 268.94M |
EBITDA | 7.03M | 34.97M | 20.71M | 28.77M | 81.85M |
Net Income | -19.93M | 6.21M | 4.49M | 14.02M | 65.82M |
Balance Sheet | |||||
Total Assets | 875.45M | 773.33M | 789.36M | 717.96M | 665.11M |
Cash, Cash Equivalents and Short-Term Investments | 61.32M | 38.18M | 90.50M | 17.93M | 77.17M |
Total Debt | 267.62M | 230.80M | 243.87M | 197.72M | 182.46M |
Total Liabilities | 661.17M | 541.50M | 567.71M | 485.50M | 438.40M |
Stockholders Equity | 214.28M | 231.79M | 221.65M | 232.46M | 226.71M |
Cash Flow | |||||
Free Cash Flow | 19.37M | 4.84M | 18.71M | -3.62M | 12.18M |
Operating Cash Flow | 88.80M | 42.89M | 58.60M | 54.30M | 110.97M |
Investing Cash Flow | -92.83M | -60.86M | -8.34M | -83.36M | -116.84M |
Financing Cash Flow | 22.89M | -32.58M | 26.67M | -32.72M | 68.21M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
75 Outperform | HK$574.62M | 4.95 | 20.67% | 20.00% | 25.95% | 44.16% | |
74 Outperform | $939.73M | 9.74 | 2.51% | 12.94% | -1.70% | 12.53% | |
56 Neutral | HK$625.71M | ― | -8.95% | ― | -3.09% | -480.17% | |
54 Neutral | HK$811.61M | 55.38 | -1.16% | 6.50% | 2.49% | -171.78% | |
52 Neutral | HK$388.35M | ― | -6.09% | ― | -30.21% | -12.78% | |
44 Neutral | AU$1.42B | -6.06 | -40.74% | 3.89% | -3.45% | -41.76% | |
41 Neutral | HK$152.00M | ― | -11.66% | ― | -31.49% | 28.61% |
SANVO Fine Chemicals Group Limited held its Annual General Meeting on June 20, 2025, where all proposed resolutions were unanimously passed. These resolutions included the adoption of financial statements, re-election of directors, and granting mandates for share issuance and repurchase, reflecting strong shareholder support and stable governance.
SANVO Fine Chemicals Group Limited has announced its 2025 Annual General Meeting, scheduled for June 20, 2025, in Hong Kong. Key agenda items include the adoption of financial statements for 2024, re-election of directors, and approval of directors’ remuneration. Additionally, the company seeks shareholder approval to authorize the board to issue new shares, which could impact the company’s market operations and shareholder value.